Highest-materiality recent filing
Odysight.ai launches $11M public offering of 3.4M shares at $3.20; terminates ATM
Offering: 3,437,500 shares at $3.20/share; gross proceeds ~$11M before discounts and expenses.
Odysight.ai prices $11M public offering of 3.44M common shares at $3.20
Priced 3,437,500 common shares at $3.20/share; gross proceeds expected ~$11M.
Odysight.ai H1 2026 revenue $0.5M, net loss $9.5M; backlog rises to $16.45M
Revenue $0.5M vs $2.4M YoY; drop driven by $1.86M prior-year medical customer revenue and $1.69M contract liability derecognition.
Odysight.ai enters $20M ATM sales agreement with Roth Capital Partners
Up to $20M of common stock may be sold at prevailing market prices through Roth Capital Partners as agent.
Odysight.ai grants COO Ronen Tanami 40,000-share option at $5.09
Ronen Tanami appointed COO on May 13, 2026; option granted May 19 under 2024 Stock Incentive Plan.
Odysight.ai Q1 revenue $82K (down 96% YoY); net loss $5.2M; backlog $14M
Revenue $82K vs $2.1M YoY; Q1 2025 included $1.7M contract liability derecognition from Fortune 500 medical customer.
Odysight.ai posts investor presentation on website; content not available in filing text
Company furnished investor presentation as Exhibit 99.1 under Item 7.01.
Odysight.ai common stock approved for dual listing on Tel Aviv Stock Exchange; trading April 9, 2026
Common stock approved for listing on TASE alongside existing Nasdaq Capital Market listing.
Odysight.ai issues 407,497 shares upon cashless exercise of 3.29M warrants
Investors exercised 3,294,117 warrants on a cashless basis on March 25, 2026.
Odysight.ai FY2025 revenue $3.0M, core PdM platform up 23%, backlog $13.8M
Total FY2025 revenue $3.0M (down 25% YoY) but core PdM/CBM platform revenue grew ~23% to $1.2M.
Odysight.ai CEO letter reveals ~$26M cash, $14M+ backlog, $10M UAV defense contract
Estimated cash balance ~$26M as of Dec 31, 2025, from $23.7M raised alongside NASDAQ uplisting.
Base salary increased by NIS 9,000 to NIS 99,000 per month, effective November 2025.
Odysight.ai annual meeting results: directors elected, incentive plan share pool increased ~70%
Elected Carlo Papa, Nir Nimrodi, Zeev Vurembrand as Class I directors with >6.3M votes each.
Odysight.ai reports $12.8M net loss on $2.6M revenue; cash $29.8M, backlog $14.2M
Revenue $2.6M in 9M2025 vs $2.7M in 9M2024; net loss widened to $12.8M from $8.2M.
Odysight.ai posts updated investor presentation on website; no specific details disclosed
Filed an updated investor presentation as Exhibit 99.1 on August 28, 2025.
Odysight.ai H1 2025 revenue $2.4M, net loss $8.3M; cash $33.2M after uplisting
Revenue $2.4M (up 71% YoY) driven by $1.7M Fortune 500 medical contract; backlog $14.4M.
Odysight.ai appoints Jacob Avinu as SVP – Head of U.S. Business Unit
Jacob Avinu appointed Senior VP – Head of U.S. Business Unit, effective Aug 1, 2025, subject to visa and relocation.
Odysight.ai Q1 revenue jumps to $2.1M from $0.2M; net loss widens to $4.3M
Revenue $2.1M (up 10x YoY) driven by $1.7M fulfillment of Fortune 500 medical contract.
Odysight.ai FY 2024 revenue $4M (+31% YoY); backlog jumps >450% to $15M
Revenue $4.0M (+31% YoY); gross margin improved to 29% from 17%.
Odysight.ai CEO salary increased to NIS 90k/month; CEO gets $142.5K bonus, 150K options
CEO Yehu Ofer monthly base salary raised from NIS 80,000 to NIS 90,000 effective Jan 1, 2025.
Odysight.ai closes over-allotment option in public offering, raising ~$23.7M gross proceeds
Over-allotment option exercised for 345,432 shares at $6.50 per share.
Odysight.ai (ODYS) prices $21.5M equity offering, begins Nasdaq trading Feb 11
Offering of 3,307,692 shares at $6.50/share; gross proceeds ~$21.5M, net proceeds ~$18.8M.
Odysight.ai adopts revised indemnification agreements for directors and officers
Board approved revised indemnification agreement on January 23, 2025, replacing prior form.
Odysight.ai posts investor presentation; no specific financial data disclosed
Presentation posted on company website on November 18, 2024, for use in investor discussions.
Odysight.ai nine-month revenue $2.7M (+145% YoY); backlog record $16M; $10M+ defense contract
Revenue $2.7M for 9M 2024 vs $1.1M YoY, driven by higher unit sales to a Fortune 500 healthcare firm and Industry 4.0.
Odysight.ai approves director compensation for Dr. Carlo Papa: €150K annual fees plus 30,000 options
Annual board service fee of €30,000 for Dr. Carlo Papa.
Repeat order from NASA for Odysight.ai's vision-based system to support high-speed aeronautical flight testing on aerospace vehicles.
Odysight.ai appoints Dr. Carlo Papa to board; CEO gets NIS 375K bonus, 60,000 options
Dr. Carlo Papa appointed to board effective Sept 16, 2024; board increases to 8 directors.
Odysight.ai receives purchase order >$10M from defense contractor for UAV predictive maintenance
Purchase order exceeding $10M from a leading international defense contractor for vision-based PdM system.
Odysight.ai reports H1 2024 revenue up 40% to $1.4M; net loss narrows to $5.3M
Revenue $1.4M (+40% YoY); gross profit $0.3M vs prior year gross loss $0.4M.
Odysight.ai secures $10.3M private placement of 2.14M shares at $4.80/share
Gross proceeds of $10.3M from 2,144,583 shares at $4.80 per share.
Odysight.ai shareholders reelect two directors and approve 2024 Share Incentive Plan
Stockholders holding >50% of outstanding shares voted by written consent on July 7, 2024.
Odysight.ai wins first purchase order from Safran Aircraft Engines for micro cameras
Inaugural purchase order from France-based Safran Aircraft Engines for Odysight.ai micro cameras.
Odysight.ai Q1 2024 net loss $3.2M; backlog $3.5M; defense orders highlight growth
GAAP net loss $3.2M and non-GAAP net loss $2.7M for Q1 2024, compared to $2.7M GAAP loss in Q1 2023.
Purchase order from Tel Aviv University for an R&D project of the Israeli Ministry of Defense.
Odysight.ai appoints Einav Brenner as CFO, effective May 5, 2024
Ms. Brenner previously served as VP Finance at Solato Ltd. and Executive Director of Finance at RedHill Biopharma (NASDAQ: RDHL).
Odysight.ai posts investor presentation; no material new information disclosed
Company posted an investor presentation on its website on April 11, 2024.
Odysight.ai 2023 revenue surges >350% to $3.0M, first gross profit of $0.5M
2023 revenue $3.0M vs $0.7M in 2022, >350% growth.
Odysight.ai receives >$1M purchase order for predictive maintenance system on IAF SH-60 Seahawk
Purchase order exceeding $1 million from major international defense contractor.
Odysight.ai appoints Tanya Yosef VP of Finance; CFO search to follow
Tanya Yosef appointed VP of Finance effective May 5, 2024.
Purchase order from Israeli Ministry of Defense to deploy PdM system on IAF Boeing AH-64 Apache attack helicopter prototype.
Odysight.ai elects two new independent directors; Inbal Kreiss reelected
Stockholders representing >50% of outstanding shares voted by written consent on Dec 6, 2023 to elect two new directors and reelect one.
Odysight.ai and SIPAL S.P.A. partner on visual health monitoring system for aerospace
Partnership combines Odysight's AI video sensors with SIPAL's Head Mounted Display for real-time aircraft inspection without panel removal.
Odysight.ai CEO Yehu Ofer elected to International Board of Weizmann Institute
CEO Yehu Ofer appointed to International Board of Weizmann Institute of Science on Nov 22, 2023.
Odysight.ai CEO to present at AI and Big Data Virtual Investor Conference on Nov 2
CEO Yehu Ofer to present at AI & Big Data Virtual Investor Conference on Nov 2, 2023 at 10:00 a.m. EDT.
Odysight.ai appoints Eli Israeli as Chief Technology Officer
Eli Israeli named CTO effective October 23, 2023; will oversee technology strategy for PdM and CBM solutions.
Odysight.ai receives $3.3M purchase order from Fortune 500 medical partner for FY2024
Expanded PO from Fortune 500 orthopaedic company totals $3.3M for fiscal year 2024.
CEO Yehu Ofer to present at Sidoti Small-Cap Virtual Conference on Sept 20
Yehu Ofer, CEO, will present at the Sidoti Small-Cap Virtual Conference on September 20, 2023 at 10:45 am ET.
Odysight.ai: $1.45M order, $2.5M revenue outlook, IAI Blackhawk deal, $14M placement
Purchase order of $1.45M from Fortune 500 healthcare customer; expects $2.5M revenue in 2023 from first-year product launch.
Odysight.ai appoints Nir Nimrodi to board of directors
Nir Nimrodi appointed to board effective August 13, 2023; board determined independent under Nasdaq rules.
The foregoing options were awarded to Mr. Tanami, who was appointed as the Chief Operating Officer on May 13, 2026, pursuant to the Company’s 2024 Stock Incentive Plan and have an exercise price of $5.09 per share.
On September 16, 2024, the Board of Directors of Odysight.ai Inc. (the “Board” and the “Company”, respectively) appointed Dr. Carlo Papa to serve as a member of the Board
On February 21, 2024, the Board resolved to appoint Ms. Einav Brenner to serve as Chief Financial Officer of the Company, which appointment shall enter into effect on May 5, 2024.
On February 21, 2024, Odysight.ai Inc. (the “ Company ”) appointed Tanya Yosef as VP of Finance for the Company, a position she is expected to begin on May 5, 2024.
On August 13, 2023, the Board of Directors of Odysight.ai Inc. (the “Board” and the “Company”, respectively) appointed Mr. Nir Nimrodi to serve as a member of the Board.
On June 1, 2023, Ronen Rosenbloom notified ScoutCam Inc. (the “Company”) that he would resign as a member of the Board of Directors effective immediately.
On July 13, 2022, the Board resolved to appoint Mr. Yehu Ofer to serve as Chief Executive Officer of the Company, which appointment shall enter into effect on October 18, 2022.
On August 12, 2022, Roee Peled, VP of Business Development for ScoutCam Ltd. (the “Company”), resigned from his position with the Company for personal reasons, effective October 30, 2022.
On July 12, 2022, ScoutCam (the “ Company ”) and Yovav Sameah, the Chief Executive Officer of the Company, mutually agreed that Mr. Sameah’s employment with the Company would terminate on October 18, 2022.
On July 6, 2021, Issac Silberman notified ScoutCam Inc. (the “Company”) by letter that he would resign as a member of the Board of Directors effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material